

Reduction of post COVID-19 condition during the Omicron wave: results from the EuCARE POSTCOVID Study

Francesca Bai¹, Alessandro Cozzi-Lepri², Pontus Hedberg³, Andrea Santoro^{1*}, Maria Francesca Greco¹, Matteo Sala¹, Julia Fonseca de Moraes Caporali⁴, Carolina Coimbra Marinho⁴, Maria Mercedes Santoro⁵, Francesca Ceccherini Silberstein⁵, Dovile Juozapaitė⁶, Edita Strumiliene⁷, André Almeida⁸, Cristina Toscano⁹, Jesus Arturo Ruiz Quinones¹⁰, Chiara Mommo¹¹, Iuri Fanti¹¹, Francesca Incardona^{11,12}, Giulia Marchetti¹ on behalf of the EuCARE Project

Affiliations: 1 Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Italy; 2 Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, UCL, London, UK; 3 Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; 4 Brazil School of Medicine, Federal University of Minas Gerais, Brazil; 5 Department of Experimental Medicine, University of Rome Tor Vergata, Roma, Lazio, Italy; 6 Vilnius Santaros Klinikos Biobank, Vilnius University Hospital Santaros Klinikos; 7 Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University; 8 Centro Universitário de Lisboa Central, Centro Clínico Académico de Lisboa, Lisboa; 9 Centro Hospitalar de Lisboa Ocidental, Lisboa; 10 Hospital Juan Graham Casaus, Villahermosa, Tab, Mexico; 11 EuResist Network, Rome, Italy; 12 IPRO-InfarmaPRO S.R.L., Rome, Italy - *Presenting author

francesca.bai@asst-santipaolocarlo.it

Background Post COVID-19 condition (PCC) has been defined as ongoing symptoms at ≥ 4 weeks after acute COVID-19. A reduction of cases is being observed following Omicron infection compared to what was seen with previous variants. We investigated the risk of PCC and PCC clusters in a cohort of hospitalized patients according to viral variants.

Methods We included hospitalized patients in 6 centers (01/2020-06/2023); a subset of patients with ≥ 1 visit over the year after clinical recovery were analyzed. Viral variants were observed or estimated by mapping with GISAID data.

Because patients returning for a post-COVID-19 visit may have a higher risk of having PCC and variant could be associated with the probability of returning, we used **weighted logistic regressions** to control for collider bias; the weights were constructed as the inverse of the propensity score of returning using a logistic model, adjusting for confounders.

We estimated the proportion of the effect of wild-type (WT) virus vs Omicron on the PCC risk, which might be mediated by Intensive Care Unit (ICU) admission/Mechanical Ventilation (MV) by a counterfactual mediation analysis.

Results 1313/7248 (18.1%) hospitalized patients returned for a post-COVID visit at a median of 2.6 (IQR 1.84-3.97) months after clinical recovery.

Omicron variant vs WT was associated with a reduced risk of PCC; conversely, we observed a higher risk with Delta and Alpha variant vs WT (Table 2). Similar results were observed using PCC clusters as outcomes.

Table 2 Odds ratios of PCC by fitting logistic regression models

VoC	Unadjusted		Adjusted	
	OR (95% CI)	p	OR (95% CI)	p
Unweighted analysis				
WT	1		1	
Alpha	1.18 (0.83-1.68)	0.352	1.23 (0.86-1.76)	0.258
Delta	1.42 (0.85-2.39)	0.184	1.35 (0.79-2.28)	0.270
Gamma	2.00 (0.92-4.35)	0.081	1.67 (0.76-3.69)	0.204
Omicron	0.22 (0.10-0.50)	<0.001	0.17 (0.07-0.40)	<0.001
Analysis weighted for VoC and demographics				
WT	1		1	
Alpha	1.14 (0.98-1.31)	0.087	1.17 (1.01-1.35)	0.042
Delta	1.46 (1.22-1.75)	<0.001	1.39 (1.16-1.67)	<0.001
Gamma	1.94 (1.19-3.17)	0.008	1.65 (1.01-2.71)	0.047
Omicron	0.21 (0.17-0.25)	<0.001	0.17 (0.14-0.21)	<0.001
Analysis weighted for VoC, demographics and CRP				
WT	1		1	
Alpha	1.32 (1.10-1.58)	0.002	1.33 (1.10-1.59)	0.003
Delta	1.44 (1.17-1.76)	<0.001	1.29 (1.05-1.60)	0.017
Gamma	1.90 (0.91-3.95)	0.085	1.68 (0.80-3.56)	0.172
Omicron	0.15 (0.13-0.18)	<0.001	0.10 (0.09-0.13)	<0.001

LEGEND: VoC, variant of concern; OR, odd ratio; CI, confidence interval. *Multivariable analysis is adjusted for age, gender, comorbidities. Unweighted analysis; model 1: weighted analysis for demographic characteristics, VoC; model 2: weighted analysis for demographic characteristics, VoC, C reactive protein (CRP).

Figure 1 Viral variants





Figure 2 PCC and main clusters



The mediation analysis showed that **41.7%** (IC95% 14.0-69.5%) of the total effect of WT virus vs Omicron variant on the PCC risk was mediated by ICU and MV (vs. no oxygen therapy). However, almost zero proportion (0, 0-4.5%) of the effect of WT strain vs. Omicron variant on the PCC risk was explained by cPAP or NIV (vs. no oxygen). The same analysis was conducted using brain fog as the outcome and we found that only a small proportion of the effect of variant on PCC was caused by disease severity (Table 3).

Table 3 Odds ratios of PCC by fitting logistic regression models

Component	WT vs. Omicron four-way Decomposition-binary outcome PCC, admission in MV-ICU as the mediator		
	Excess RR (95% CI)	Proportion Attributable (95% CI)	p value
CDE ¹	3.41 (-1.53, 8.34)	74.8 (53.6, 95.9)	<0.001
INT-ref ²	-0.75 (-2.18, 0.67)	-16.5 (-36.2, 3.2)	0.100
INT-med ³	1.65 (-0.79, 4.10)	36.3 (15.0, 57.6)	<0.001
PIE ⁴	0.25 (-0.05, 0.55)	5.4 (-3.4, 14.3)	0.228
TERR ⁵	4.56 (-1.48, 10.60)	100.0	
ORTE ⁶	5.56 (1.00, 11.60)		
Overall proportion due to Interaction		19.8 (5.1, 34.4)	
Overall proportion due to Mediation		41.7 (14.0, 69.5)	

LEGEND: 1. Controlled Direct Effect (neither mediation nor interaction); 2. Reference Interaction (interaction but not mediation); 3. Mediated Interaction (both mediation and interaction); 4. Pure Indirect Effect (mediation but no interaction); 5. Total excess relative risk; 6. Odds ratio total effect. Model adjusted for age, sex and comorbidities.

Table 1 Characteristics of the study population according to viral variants

VoC	WT virus N 975	Alpha N 183	Delta N 84	Gamma N 44	Omicron N 27	p values
Age, median (IQR)	59 (50, 68)	59 (51, 69)	58 (48, 73)	57(47, 65)	77 (69, 84)	<0.001
Female, n (%)	397 (40.7%)	74 (40.4%)	39 (46.4%)	28. (63.6%)	11 (40.7%)	0.041
Italian, n (%)	362 (37.1%)	122 (66.7%)	26 (31%)	0 (0%)	20 (74.1%)	<0.001
Comorbidities, n (%)	595 (61%)	96 (52.5%)	54 (64.3%)	34 (77.3%)	21 (77.8%)	0.007
Vaccination, 2+ doses, n (%)	0 (0%)	0 (0%)	27 (32.5%)	0 (0%)	5 (31.3%)	<0.001

LEGEND: Categorical variables are presented as absolute n, percentages, quantitative variables as median, interquartile range. Chi-square and Kruskal Wallis test for comparison.

Conclusions

Most common phenotypes of PCC are **fatigue, respiratory sequelae and brain fog**. A reduced risk of PCC was observed following **Omicron infection** compared to WT virus, suggesting a possible reduction of the burden of PCC over time. A large proportion of the effect of WT virus compared to Omicron variant on PCC risk appeared to be mediated by an **increased disease severity during the acute phase**.